I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Label No. EV 755073602 US, on the date shown below in an envelope addressed to:

Mail Stop PCT, Commissioner for Patients, P.O. Boy-4450, Alexandrja-yA 22313-1450.

Dated: August 9, 2006

ignature:

Docket No.: 60879(72021)

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Rajagopal Bakthavatchalam et al.

Application No.: 10/564,431

Filed: January 10, 2006

For: SUBSTITUTED HETEROCYCLIC

DIARYLAMINE ANALOGUES

Confirmation No.: 1519

Art Unit: N/A

Examiner: Not Yet Assigned

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir.

In response to the Notification of Missing Requirements mailed June 9, 2006 ("the Notification"), Applicant respectfully submits (i) a Declaration for Patent Application, and (ii) a copy of the Notification.

The Notification indicated that a Sequence Listing (in paper and computer-readable forms) in compliance with 37 CFR 1.821-1.825 is required. Applicants respectfully disagree. The present application does not disclose any nucleotide or amino acid sequences that would require the submission of a sequence listing. The only mentions of nucleotide or amino acid sequences found by the undersigned occur at pages 13 (lines 18-21) and 73 (lines 6-7), where certain sequences disclosed in an issued U.S. patent are mentioned, but this reference does not constitute a "disclosure" of such sequences for purposes of compliance with 37 CFR 1.821-1.825. Accordingly.